Reviewing Riot Blockchain (RIOT) & Arca Biopharma (ABIO)

Riot Blockchain (NASDAQ:RIOT) and Arca Biopharma (NASDAQ:ABIO) are both small-cap business services companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Volatility & Risk

Riot Blockchain has a beta of 2.66, suggesting that its share price is 166% more volatile than the S&P 500. Comparatively, Arca Biopharma has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Riot Blockchain and Arca Biopharma, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Riot Blockchain 0 0 1 0 3.00
Arca Biopharma 0 0 1 0 3.00

Riot Blockchain presently has a consensus price target of $4.00, indicating a potential upside of 115.05%. Arca Biopharma has a consensus price target of $2.00, indicating a potential upside of 287.82%. Given Arca Biopharma’s higher probable upside, analysts plainly believe Arca Biopharma is more favorable than Riot Blockchain.

Earnings & Valuation

This table compares Riot Blockchain and Arca Biopharma’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Riot Blockchain $170,000.00 158.65 -$19.84 million ($2.71) -0.69
Arca Biopharma N/A N/A -$18.49 million N/A N/A

Arca Biopharma has lower revenue, but higher earnings than Riot Blockchain.


This table compares Riot Blockchain and Arca Biopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Riot Blockchain -883.37% -92.58% -67.12%
Arca Biopharma N/A -112.69% -97.53%

Insider & Institutional Ownership

14.1% of Riot Blockchain shares are held by institutional investors. Comparatively, 16.0% of Arca Biopharma shares are held by institutional investors. 2.7% of Riot Blockchain shares are held by insiders. Comparatively, 3.6% of Arca Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.


Arca Biopharma beats Riot Blockchain on 5 of the 9 factors compared between the two stocks.

About Riot Blockchain

Riot Blockchain, Inc. focuses on building, supporting, and operating blockchain technologies, primarily through its cryptocurrency mining operations and other developed businesses, as well as joint ventures, acquisitions, and targeted investments in the sector. Its primary focus is on Bitcoin and general blockchain technology. The company leverages its expertise and network to build and support blockchain technology companies. It builds a cryptocurrency mining operation and operates specialized computers that generate cryptocurrency, primarily Bitcoin. The company also holds interests in various activities, including purchasing and selling cryptocurrencies; providing accounting, audit, and verification services for blockchain based assets, such as cryptocurrencies; and developing TessPay, a payments ecosystem for component and sub-component supply chain settlements, and other blockchain solutions for telecommunications companies. As of March 31, 2018, approximately 3,500 of the miners were installed and operating. The company was formerly known as Bioptix, Inc. and changed its name to Riot Blockchain, Inc. in October 2017. Riot Blockchain, Inc. was founded in 2000 and is based in Castle Rock, Colorado.

About Arca Biopharma

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction. It also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic heart failure. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Receive News & Ratings for Riot Blockchain Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Riot Blockchain and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit